AGENUS INC Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested
AGENUS INC (AGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested of $7.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested · last filed 2026-03-16
- AGENUS INC share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2018-12-31 was $42.00K, a 97.67% decline year-over-year.
- AGENUS INC share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2018-09-30 was $0.00.
- AGENUS INC share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2018-06-30 was $0.00, a 100.00% decline year-over-year.
- AGENUS INC share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2018-03-31 was $200.00K, a 669.23% increase year-over-year.
- AGENUS INC share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2025 was $7.80M, a 3800.00% increase from fiscal 2024.
- AGENUS INC share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2024 was $200.00K, a 98.26% decline from fiscal 2023.
- AGENUS INC share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2023 was $11.50M, a 5.50% increase from fiscal 2022.
- AGENUS INC share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2022 was $10.90M, a 87.93% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 12 month |
|---|---|---|---|---|
| 2025-12-31 | $7.80M 10-K · filed 2026-03-16 | |||
| 2024-12-31 | $200.00K 10-K · filed 2026-03-16 | |||
| 2023-12-31 | $11.50M 10-K · filed 2026-03-16 | |||
| 2022-12-31 | $10.90M 10-K · filed 2025-03-17 | |||
| 2021-12-31 | $5.80M 10-K · filed 2024-03-14 | |||
| 2020-12-31 | $621.00K 10-K · filed 2023-03-16 | |||
| 2019-12-31 | $357.00K 10-K · filed 2022-03-01 | |||
| 2018-12-31 | $42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $42.00K derived: sum of 2 quarters · filed 2021-03-16 | $42.00K derived: sum of 3 quarters · filed 2021-03-16 | $242.00K 10-K · filed 2021-03-16 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $200.00K 10-Q · filed 2018-11-07 | $2.00M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $200.00K 10-Q · filed 2018-08-09 | $2.00M derived: sum of 3 quarters · filed 2020-03-16 | $2.00M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-03-31 | $200.00K 10-Q · filed 2018-05-10 | $2.00M derived: sum of 2 quarters · filed 2020-03-16 | $2.00M derived: sum of 3 quarters · filed 2020-03-16 | $3.97M derived: sum of 4 quarters · filed 2020-03-16 |
| 2017-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $1.80M derived: sum of 2 quarters · filed 2020-03-16 | $3.77M derived: sum of 3 quarters · filed 2020-03-16 | $3.80M 10-K · filed 2020-03-16 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $1.97M derived: sum of 2 quarters · filed 2017-11-07 | $2.00M 10-Q · filed 2017-11-07 | $2.00M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-06-30 | $1.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $2.00M 10-Q · filed 2017-08-07 | $2.00M derived: sum of 3 quarters · filed 2019-03-18 | |
| 2017-03-31 | $26.00K 10-Q · filed 2017-05-04 | $26.00K derived: sum of 2 quarters · filed 2019-03-18 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $2.40M 10-K · filed 2019-03-18 | ||
| 2016-09-30 | $2.40M 10-Q · filed 2016-11-09 | |||
| 2015-12-31 | $140.00K 10-K · filed 2018-03-16 | |||
| 2014-12-31 | $205.00K 10-K · filed 2017-03-16 | |||
| 2013-12-31 | $1.60M 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |